$VEEV

Veeva Announces Fiscal 2027 Second Quarter Results

Veeva Systems reported Q2 2027 results with total revenue of $928.0M, up 18% YoY, and subscription revenue of $766.8M, up 16% YoY. Operating income increased 40% YoY to $275.0M. The company raised its full-year guidance and highlighted growth in AI-driven products like Vault CRM and Falcon. CEO Peter Gassner emphasized AI's role in driving efficiency in the life sciences industry.

Original reporting
Published Aug 26, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 9:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Veeva Announces Fiscal 2027 Second Quarter Results — source image
Decision brief

The 30-second read

$VEEVBullishMed
01

Why it matters

The earnings beat and raised guidance are likely to drive short‑term buying pressure, while long‑term valuation will depend on AI adoption rates.

02

Market read

Veeva's strong earnings and forward outlook make it a focal point for investors in the health‑tech SaaS space.

03

What to watch

Potential headwinds from regulatory scrutiny of AI in healthcare and competitive pressure from larger cloud players.

Relevance 8/10Novelty 8/10Timing: today, pre‑market

Background

Veeva's Q2 release includes detailed financials, AI product updates, and guidance for FY2027.

Company-level read

Ticker impact

$VEEVBullishHigh confidence
Context

Veeva Systems reported Q2 FY2027 results with revenue up 18% YoY and raised FY guidance, a primary earnings disclosure.

Expected impact

Expect modest upside in the near‑term as investors price in higher revenue guidance.

Evidence & confidence

Revenue beat and guidance lift are fresh, material facts for a mid‑cap SaaS company; market typically reacts positively to such earnings surprises.

Market effects

Reinforces bullish outlook for cloud‑software providers serving life‑sciences, potentially lifting peers.

Positive for U.S. technology sector, especially SaaS and health‑tech stocks.

Highlights growing AI adoption in life‑sciences, a theme of interest to global investors.

Counterpoint

If the AI‑driven growth does not translate into margin expansion, the stock could face pressure despite top‑line beat.

Key entities

  • Peter Gassner

    CEO of Veeva Systems, quoted on AI strategy.

  • Brian Van Wagener

    CFO of Veeva Systems, highlighted financial performance.

Related articles

$NVDAHighAI 8/10

Stocks making the biggest moves after hours: Nvidia, Salesforce, CrowdStrike, Urban Outfitters and more

Nvidia, Salesforce, Okta, Agilent, CrowdStrike, Everpure, Veeva, Urban Outfitters, and Synopsys reported earnings. Nvidia, Salesforce, Okta, Agilent, CrowdStrike, Everpure, and Veeva exceeded expectations, while Urban Outfitters met estimates and Synopsys fell. Nvidia reported $2.22 EPS and $96.22B revenue, raising Q3 guidance to $108B. Salesforce reported $11.35B revenue and $5.90 EPS. Okta raised full-year guidance. Synopsys raised annual revenue and profit forecasts but shares fell 2%.

$VEEVHighAI 9/10

Why is Veeva Systems stock surging today?

Veeva Systems (VEEV) stock rose 8.1% after reporting fiscal Q2 2027 results that exceeded expectations, with subscription revenues of $766.8M, up 16% YoY. The company raised full-year guidance, and analysts increased the price target to $314.71. Biogen and Regeneron announced commitments to Veeva's Vault CRM platform, driving demand for its AI-powered commercial suite. The broader market had minimal impact on Veeva's after-hours move, which was driven by company-specific catalysts.

$VEEVLow

Veeva Systems Taps Dan Rizzo to Lead Global Sales as Veteran Executive Departs — BigGo Finance

Veeva Systems (VEEV) appointed Dan Rizzo as executive vice president of sales, consulting, and services, replacing Thomas D. Schwenger, who is leaving to become CEO at a partner company. The change comes as Veeva secures a global deployment deal with Eli Lilly, reinforcing its position in the life sciences industry. Investors will watch Veeva's upcoming quarterly results for insights on sales pipeline, customer retention, and suite adoption rates. The company projects revenue of $4.7B and earnin